JO
MNPR icon

John Overdeck’s Monopar Therapeutics MNPR Stock Holding History

John Overdeck’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
12,252
+2,487
+25% +$154K ﹤0.01% 3515
2026
Q1 		$535K Buy
9,765
+4,776
+96% +$288K ﹤0.01% 3696
2025
Q4 		$326K Buy
+4,989
New +$408K ﹤0.01% 3541
2024
Q1 		– Sell
-2,860
Closed -$4.87K – 3244
2023
Q4 		$4.87K Buy
+2,860
New +$5.79K ﹤0.01% 3103

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

John Overdeck's MNPR Position: Q2 2026 in Review

John Overdeck increased its Monopar Therapeutics (MNPR) stake by 25% in Q2 2026, buying an estimated $154K and bringing the position to 12,252 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3515.

John Overdeck first reported a position in MNPR in Q4 2023 and has held it in 4 quarters since. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • John Overdeck held 12,252 shares of Monopar Therapeutics worth $1.13M as of Q2 2026.
  • John Overdeck bought 2,487 Monopar Therapeutics shares in Q2 2026, an estimated $154K.
  • Monopar Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3515 holding.
  • John Overdeck first reported a position in Monopar Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.